Skip to content
menu-icon-lq
close-icon-lq
EQA

New schemes

We actively follow the development of laboratory medicine as we want to produce clinically relevant EQA schemes to serve clinical laboratories and point-of-care sites. We launch new pilot studies on a regular basis and aim to increase our EQA portfolio with 5-10 new EQA schemes every year.

Planned pilot studies for 2023/2024

We are planning new EQA pilot studies for 2023/2024. The arranged pilots will be free of charge for a limited number of participants.

 If you registered for one or more pilots through the general registration link earlier this year, we will send you more information as the pilot approaches. This year, we are also including a short survey in the pilot studies. By responding, you can give us important information on how we can make the EQA scheme better for you.

This page will be updated as further studies are scheduled.

Registration for these upcoming pilot studies has closed. They are performed during October-November 2023 and you can find the new schemes in our program for 2024.

600x350 categories-18

Helicobacter pylori, nucleic acid detection

Labquality is announcing a new EQA scheme for nucleic acid detection of Helicobacter pylori. The scheme will be suitable for different methods.

The registration for this pilot study is closed.

600x350 categories-20

Maternal Serum Screening

Labquality is announcing a new EQA scheme for Maternal serum screening suitable for first and/or second-trimester screenings including analytes AFP, b-hCG, Inhibin A, PAPP-A, total hCG and unconjugated Estriol.

The registration for this pilot study is closed.

600x350 categories-17

Mycoplasma genitalium, drug resistance multiplex, nucleic acid detection

Labquality is announcing a new EQA scheme for Mycoplasma genitalium, drug resistance multiplex, nucleic acid detection. The scheme is suitable for nucleic acid assays detecting Mycoplasma genitalium and mutations
in the 23S rRNA gene that are associated with resistance to azithromycin (macrolide antibiotic).

The registration for this pilot study is closed.

600x350 categories-22

Pipette control

Labquality is announcing a new EQA scheme for controlling and monitoring single-channel piston pipettes used in clinical laboratories. This EQA scheme offers the possibility for clinical laboratories to perform intermediate performance checks between pipette calibration intervals including interlaboratory comparison and individual performance assessment against a reference measurement value.

The registration for this pilot study is closed.

All planned pilot studies for 2023/2024

Bacteriology: H. pylori, nucleic acid detection
Bacteriology: Bone and joint infections, multiplex, nucleic acid detection
Bacteriology: Vaginitis/Vaginosis, multiplex, nucleic acid detection
Bacteriology: Gram stain, vaginal fluid
Bacteriology: Blood culture pathogens (sepsis), multiplex, nucleic acid detection
Bacteriology: Mycoplasma genitalium, drug resistance, nucleic acid detection
Clinical chemistry:
Maternal screening
Haematology: Flow cytometry, Immunophenotyping, lymphocyte subsets

Immunology: ASCA, Anti-Saccharomyces cerevisiae, antibody detection
Mycology:
Fungal infection, native and fluorescence virtual microscopy
Parasitology:
Leishmania, nucleic acid detection
Virology:
HPV-induced head and neck cancer control
Virology: Norovirus, antigen detection
Virology: West Nile virus, antibody detection
EQA for POCT
EQA for molecular pathology

Recently performed pilot studies

Salivary Cortisol

Labquality is announcing a new EQA scheme for Salivary Cortisol. The scheme is suitable for different assays measuring salivary cortisol in clinical samples. The registration for this pilot study is closed. 

Chemokine CXCL13

Labquality is announcing a new EQA scheme for Chemokine CXCL13, a biomarker for neuroborreliosis. Pilot round includes two samples that should be analysed as regular patient samples. The registration for this pilot study is closed.

Interferon Gamma Release Assay (IGRA) for Mycobacterium tuberculosis

Labquality is announcing a new EQA scheme for Interferon Gamma Release Assay (IGRA) for Mycobacterium tuberculosis. The scheme is suitable for different ELISA assays measuring the cell-mediated response to specific tuberculosis antigens in whole blood. The sample sets are sold out and we can only accept registrations for a waiting list. The registration for this pilot study is closed. 

Faecal Elastase

Labquality is announcing a new EQA scheme for faecal elastase. In the pilot study, two lyophilized faecal samples of different elastase concentration will be included. The registration for this pilot study is closed. 

Fungal infections, nucleic acid detection

Labquality is announcing a new EQA scheme for direct nucleic acid detection of fungal infections. The scheme samples may contain yeasts, moulds and dermatophytes and it will be suitable for different nucleic acid test panels. The registration for this pilot study is closed. 

Mycobacterium tuberculosis, rifampicin and isoniazid, nucleic acid detection

Labquality is announcing a new EQA scheme for nucleic acid detection of Mycobacterium tuberculosis including samples containing rifampicin and isoniazid resistance. The scheme is suitable for nucleic acid test panels and scoring is based on qualitative interpretation. The registration for this pilot study is closed. 

Adrenocorticothropic hormone ACTH and Cortisol

Labquality is announcing a new pilot study for two hormones ACTH and cortisol. The registration for this pilot study is closed. 

HSV1&2 / VZV / T. pallidum, nucleic acid detection

Labquality is announcing a new pilot study for nucleic acid detection of four pathogens included in a four-plex sample. The included pathogens are HSV1&2, VZV and Treponema pallidum. The registration for this pilot study is closed. 

EQA for next-generation sequencing methods

We are developing external quality assessments for NGS methods in microbiology. If you are interested, please contact us!

Contact us for more information!

Heidi Berghäll
Heidi Berghäll
EQA Solutions Manager, R&D
Kristel Virtanen
Kristel Virtanen
EQA Solutions Manager, IT

Related Services

EQA Program
EQA

EQA Programme 2023

Labquality’s external quality assessment program (EQAS) is aimed at medical laboratories and point-of-care testing sites.

Read more
External Quality Assessment
EQA

External Quality Assessment

Labquality’s EQA schemes are designed for medical laboratories and point-of-care testing sites to monitor and improve their performance.

Read more
Integrated EQA Service
EQA

Integrated EQA Service

Integrated EQA service is a completely new approach to external quality assessment.

Read more
Labquality’s Partners in EQA
EQA

Labquality’s Partners in EQA

Labquality has EQA partners in more than 40 countries in Europe, South America, South-East Asia and the Middle East. Please find the contact details here.

Read more
External Quality Assessment Services
EQA

External Quality Assessment Services

Our external quality assessment service programme includes more than 160 EQA schemes, covering the key specialities of laboratory medicine.

Read more
EQAS for preanalytical phase
EQA

EQAS for preanalytical phase

Labquality’s preanalytical external quality assessment schemes provide a unique means to assess a larger part of the total laboratory testing cycle.

Read more

Subscribe to our newsletter

Subscribe to hear the latest news in the industry and keep track of what's happening behind the scenes.